Wuxi Bio submitted a next-day disclosure report on September 2, 2024, disclosing the changes in its shareholding. The report shows that on September 2, 2024, the company repurchased 5,480,000 common shares at a repurchase price ranging from HKD 10.82 to HKD 10.98, with a total payment price of HKD 59,811,610. This repurchase accounts for 0.1319% of the issued shares and the company plans to cancel these shares. In addition, on June 11, 2024, the company repurchased 1,810,000 shares, but they have not been cancelled yet. Wuxi Bio confirms that all share repurchases were conducted in accordance with the rules of the Hong Kong Stock Exchange and have been officially authorized by the board of directors. After the repurchase, the company will enter a one-month moratorium period until October 2, 2024.

Wuxi Bio submitted a next-day disclosure report on September 2, 2024, disclosing the changes in its shareholding. The report shows that on September 2, 2024, the company repurchased 5,480,000 common shares at a repurchase price ranging from HKD 10.82 to HKD 10.98, with a total payment price of HKD 59,811,610. This repurchase accounts for 0.1319% of the issued shares and the company plans to cancel these shares. In addition, on June 11, 2024, the company repurchased 1,810,000 shares, but they have not been cancelled yet. Wuxi Bio confirms that all share repurchases were conducted in accordance with the rules of the Hong Kong Stock Exchange and have been officially authorized by the board of directors. After the repurchase, the company will enter a one-month moratorium period until October 2, 2024.